^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Sym013
i
Other names: Sym013
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Servier
Drug class:
EGFR inhibitor, HER2 inhibitor, HER3 inhibitor
Related drugs:
almost3years
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies. (PubMed, Invest New Drugs)
During the conduct of the study, management of frequent infusion-related reactions, skin toxicities, and mucosal disorders, which are indicative of HER inhibition, necessitated multiple protocol amendments. The investigators, in concert with the Sponsor, agreed that achieving a tolerated regimen with acceptable target saturation was unlikely.
P1 data • PK/PD data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
Sym013
over3years
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. (PubMed, MAbs)
Finally, we demonstrated that the Pan-HER and gemcitabine combination has an additive effect in vitro and in mice xenografted with the gemcitabine-sensitive or resistant pancreatic models. The mixture of anti-EGFR, HER2 and HER3 antibodies is a good candidate therapeutic approach for gemcitabine-sensitive and -resistant pancreatic cancer.
Preclinical • Journal
|
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 expression • ERBB3 expression
|
gemcitabine • Sym013
Share via
